Loading
A T-cell receptor engineered to see a peptide from inside the cell presented on an HLA molecule: the antigen and the HLA restriction together decide who the medicine can treat. The corpus holds 5 tcr-t cell therapies medicines: 1 approved, 2 in phase 3, 3 trials recruiting, 5 companies named. Every section below says which records it was read from.
From 1 record:TCR-T cell therapy
T cells engineered with a receptor that sees fragments of proteins inside the cancer cell, reaching targets CAR-T cannot.
Transgenic αβ TCR recognises a peptide-HLA complex; restricted to patients with the matching HLA allele.
From 5 records:Afamitresgene autoleucelIMA203Letetresgene autoleucelTAC01-CLDN18.2TBI-1301
Target against hla restriction, 4 by 1. Open the grid, where every cell links to its medicines and the records behind its state.
From 1 record:Afamitresgene autoleucel
From 5 records:Afamitresgene autoleucelIMA203Letetresgene autoleucelTAC01-CLDN18.2TBI-1301
From 5 records:US WorldMedsAdaptimmuneImmaticsTakara BioTriumvira Immunologics
| Company | Type | Medicines | Approved | Phase 3 | Which |
|---|---|---|---|---|---|
| US WorldMeds US | pharma | 2 | 1 | 0 | |
| Adaptimmune GB | cell therapy | 1 | 1 | 0 | |
| Immatics DE | cell therapy | 1 | 0 | 1 | |
| Takara Bio JP | cell therapy | 1 | 0 | 1 | |
| Triumvira Immunologics US | cell therapy | 1 | 0 | 0 |
From 3 records:Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial SarcomaSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaSPEARHEAD-3 Pediatric Study
| Registry | ||||||
|---|---|---|---|---|---|---|
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With N… | Phase 3 | Takara Bio | 5 | NCT07174427 | ||
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group P… | Phase 3 | Immatics US | 360 | NCT06743126 | ||
SPEARHEAD-3 Pediatric Study A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Ac… | Phase 1/2 | USWM CT, LLC | 20 | NCT05642455 |
From 1 record:Letetresgene autoleucel
A flood of inflammatory signals when immune cells are activated en masse, causing fever, low blood pressure, and sometimes organ failure.
Linked fromLetetresgene autoleucel
From no record yet:
The resistance atlas records no class whose exemplars are medicines of this format.
From 6 records:TCR-T cell therapyAfamitresgene autoleucelIMA203Letetresgene autoleucelTAC01-CLDN18.2TBI-1301
SPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma T cells engineered with a receptor recognising the MAGE-A4 cancer antigen shrank tumours in 37% of patients with advanced synovial sarcoma… | 2,024 | The Lancet | translational | |
SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma T cells taken from patients and engineered to recognise the MAGE-A4 protein shrank tumours in about four in ten patients with advanced syno… | 2,024 | The Lancet | rct |
From 2 records:Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CARKRAS roadmap: undruggable → G12C → pan-RAS
From 6 records:TCR-T cell therapyAfamitresgene autoleucelIMA203Letetresgene autoleucelTAC01-CLDN18.2TBI-1301
Hospital-exemption cell therapies at scale, backed by a shared registry European law already lets hospitals make advanced therapies for their own patients. Pair that with a shared outcomes registry so academic CAR-Ts and similar tr… | Early clinical | |
Public cell-therapy foundries at cancer centres for academics and start-ups Building a cell-therapy factory costs tens of millions, so most good academic ideas never reach patients. Shared public facilities would give them a route to t… | Early clinical | |
Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface Cells chop up their internal proteins and display the pieces on their surface. That means even undruggable proteins inside the cell can be attacked from outsid… | Preclinical evidence | |
Extending sarcoma TCR-T beyond HLA-A*02 Today's engineered T-cell therapies for sarcoma only work in the ~40-50% of people with one particular HLA type; new receptors for other HLA types would open t… | Preclinical evidence | |
TCR therapeutics for non-HLA-A*02 patients Today's T-cell-receptor drugs only work for people with one tissue type. Building versions for the other common types would roughly double who can be treated. | Preclinical evidence | |
What makes a neoantigen actually immunogenic? Vaccines can now encode dozens of a tumour's mutations, but only a minority provoke useful T cells. Learning the rules would make vaccines smaller, cheaper, an… | Preclinical evidence | |
Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer For people at very high cancer risk, install a small population of engineered immune cells that live for years and destroy cells showing early cancer signals b… | Speculative | |
Shared splice-derived neoantigens as off-the-shelf vaccine targets Mutations in the RNA splicing genes SF3B1, SRSF2 and U2AF1 produce the same mis-spliced proteins in patient after patient with MDS, CLL or uveal melanoma. If f… | Speculative |
From no record yet:
Apheresis, vector, closed manufacturing, cryopreservation and chain of identity, release testing, point of care and allogeneic banks.
Apheresis and starting-material collectionViral vector manufacturing (lentiviral, retroviral, AAV)Autologous CAR-T manufacturing, batch by batchClosed automated cell-therapy manufacturingCryopreservation and cell-therapy cold chainCell-therapy orchestration and chain-of-identity softwareCell-therapy release and potency testingPoint-of-care and decentralised cell manufacturingAllogeneic cell banks: one donor, hundreds of doses
CompaniesNovartisGilead Sciences (incl. Kite)Bristol Myers SquibbLegend BiotechAutolus TherapeuticsOXB (Oxford Biomedica)Miltenyi BiotecCytiva (Danaher)LonzaCellaresCryoportTerumo Blood and Cell TechnologiesCellectisAllogene TherapeuticsImmunoACT
| Site | Operator | Capabilities | Makes | Source |
|---|---|---|---|---|
| Bristol Myers Squibb Devens Devens, Massachusetts, US · in-house | Bristol Myers Squibb | Cell therapyAntibody drug substance | BMS manufacturing | |
| Cellares Smart Factory South San Francisco, California, US · contract manufacturer | Cellares | Cell therapy | Cellares | |
| Kite El Segundo El Segundo, California, US · in-house | Kite (Gilead) | Cell therapy | Kite manufacturing | |
| Kite Frederick Frederick, Maryland, US · in-house | Kite (Gilead) | Cell therapyViral vector | Kite manufacturing | |
| Kite Hoofddorp Hoofddorp, NL · in-house | Kite (Gilead) | Cell therapy | Kite manufacturing | |
| Legend Biotech and Janssen Raritan Raritan, New Jersey, US · in-house | Legend Biotech with Johnson & Johnson | Cell therapy | Legend Biotech | |
| Legend Biotech Ghent (Tech Lane) Ghent, BE · in-house | Legend Biotech with Johnson & Johnson | Cell therapy | Legend Biotech | |
| Miltenyi Biotec Bergisch Gladbach, DE · contract manufacturer | Miltenyi Biotec | Cell therapyViral vector | Miltenyi Biotec | |
| Novartis Morris Plains Morris Plains, New Jersey, US · in-house | Novartis | Cell therapy | Novartis cell therapy | |
| Oxford Biomedica Oxbox Oxford, GB · contract manufacturer | Oxford Biomedica | Viral vector | Oxford Biomedica |
The manufacturing map draws every site and the seven supply chains.
No manufacturing technology record is listed for this format.
The medicines are the ones the open drug engine files under tcr-t cell therapies, whether it placed them on its grid or listed them as unresolved. The technology records are listed by hand (src/lib/modular-formats.ts) and each carries a pill back here. Everything else follows the graph's links from those two sets: approvals, cancers and toxicity from the medicine records; companies, trials, papers and ideas from the records that name a medicine or technology; roadmap steps from their refs; resistance from the atlas; manufacturing from the site and supply chain records.
Nothing here is written for the hub. Where the corpus holds no record for a section, the section says so rather than filling the gap, and the counts are counts of records in OnCo, not of the world. The JSON companion carries every section with the record ids behind it. Not medical advice.